Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in advanced sarcomatoid carcinoma
NCT05265793Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in sarcomatoid carcinoma and carcinosarcoma, sponsored by Fudan University. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
sarcomatoid carcinomacarcinosarcoma
Beyond the preview
Go deeper on NCT05265793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265793.